Treatment of Chronic UTI Caused by ESBL-Producing Klebsiella pneumoniae

Initial Targeted Therapy Selection

The European Society of Clinical Microbiology and Infectious Diseases recommends carbapenems (imipenem, meropenem, or ertapenem) as the first-line targeted therapy for ESBL-producing Enterobacterales infections, including chronic UTI caused by ESBL-producing Klebsiella pneumoniae without septic shock, with consideration for oral step-down options based on susceptibility testing once clinically stable 1
For patients without septic shock, ertapenem may be preferred over imipenem or meropenem as it offers comparable efficacy with once-daily dosing and carbapenem-sparing benefits 1
Ertapenem dosing should follow a standard regimen based on renal function 1

For low-risk, non-severe chronic UTI, consider aminoglycosides (gentamicin 5-7 mg/kg/day IV once daily or amikacin 15 mg/kg/day IV once daily) when active in vitro for short durations, as recommended by the Infectious Diseases Society of America 1, 2
IV fosfomycin is conditionally recommended for chronic UTI without septic shock, according to the European Society of Clinical Microbiology and Infectious Diseases 1
Piperacillin-tazobactam, amoxicillin-clavulanate, or quinolones may be considered for non-severe infections under antibiotic stewardship principles, but only if susceptibility is confirmed, as suggested by the American College of Physicians 1

Do NOT use tigecycline for UTI treatment, as it is strongly not recommended for ESBL infections and specifically contraindicated for bloodstream infections, according to the Infectious Diseases Society of America 1, 2
Avoid cephamycins (cefoxitin, cefmetazole) and cefepime, as these are conditionally recommended against for ESBL infections, as stated by the European Society of Clinical Microbiology and Infectious Diseases 1
Reserve newer beta-lactam/beta-lactamase inhibitors (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam) for carbapenem-resistant organisms only, due to antibiotic stewardship considerations, as recommended by the American College of Physicians 1, 2

In patients with impaired renal function, ertapenem is strongly preferred over aminoglycosides due to the substantial nephrotoxicity risk of gentamicin, which can accumulate and cause toxicity even with short courses, as noted by the National Kidney Foundation 3
Aminoglycosides reach urinary concentrations 25-100 fold higher than plasma levels but carry significant nephrotoxicity risk after 7 days (or earlier with pre-existing renal impairment), according to the National Kidney Foundation 3

Step-down to oral therapy is good clinical practice once the patient is stabilized, as recommended by the Infectious Diseases Society of America 1
Options include older beta-lactam/beta-lactamase inhibitors, quinolones, or cotrimoxazole based on susceptibility patterns, as suggested by the American College of Physicians 1

Standard duration for chronic UTI is 5-10 days, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 4

Obtain susceptibility testing to guide therapy, as ESBL-producing organisms often carry multiple resistance mechanisms, according to the Infectious Diseases Society of America 1